Investors gave a lot of value to Namita Thapar’s company, IPO was subscribed 68 times, how will the stock be listed

Emcure Pharmaceuticals IPO Final Subscription : The IPO of Shark Tank judge Namita Thapar’s company Emcure Pharmaceuticals has received bumper subscription today on the last day, 5 July 2024. This IPO has been subscribed 68 times or 6800 percent by 5 pm on its third day. There is a craze in the grey market about the IPO. At the same time, brokerage houses are also positive on the company’s outlook. Now investors will wait for the shares to be allotted. Share allotment is on July 8 and listing is on July 10.

Sensex @80K: Bullish momentum in the market, best 21 largecap and midcap stocks for portfolio

Subscribed 68 times so far

Emcure Pharmaceuticals’ IPO has been subscribed 68 times overall on its third day. 35% of the IPO is reserved for retail investors and it has been subscribed 7.30 times overall. 50% of it is reserved for qualified institutional buyers (QIB) and it has been subscribed 191.24 times. While 15% is reserved for non-institutional investors (NII) and it has been subscribed 49.27 times overall. The portion reserved for employees has been subscribed 8.77 times.

Grey Market Premium (GMP) 33%

On the third day of the IPO of Emcure Pharmaceuticals, the craze for its unlisted stock has increased in the grey market. The unlisted stock of the company is seen at a price of Rs 330 in the grey market, which is a 33 percent premium over the upper price band of Rs 1008.

Subscribe for a long term

Brokerage house Geojit says that Emcure Pharma’s IPO can be subscribed from a long-term perspective. At the upper price band of 1008, Emcure Pharma is available at EPL P/E of 36x (FY24), which looks fully priced. Given its strong research and development expertise in differentiated products, established domestic and international presence, strong focus on the healthcare market for women, improving profitability after the IPO and diversified product portfolio, the brokerage has recommended subscription in it for the mid to long term.

These stocks could not even beat the returns of FD in 5 years, got returns of only 1 to 4.50%, have you invested in any of them

Company Strength

• Well positioned to take advantage of leverage in the domestic market

• Demonstrated capabilities of building brands

• Large, diversified and rapidly growing product portfolio in international markets

• Strong research and development capabilities drive a differentiated portfolio of products.

• Extensive and diversified manufacturing capacity

• Increasing market share in the domestic market.

• Continue to invest in research and development and manufacturing capabilities to enhance and develop a differentiated product portfolio.

• Deepening and expanding international presence with a focused go-to-market approach.

• Pursuing strategic acquisitions, partnerships and in-licensing arrangements.

Risk with the company

A significant portion of domestic revenues, 57 per cent in FY14, comes from acute therapies, which are subject to strong competition.